Neogenomics Inc (NEO) Stock Price, Quote & News

Company Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-s...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 239 768 0600

Fax: 239 690 4237

Website: www.neogenomics.com

Address:

9490 NeoGenomics Way, Fort Myers, United States

JarvisFlow Aug. 4 at 3:59 PM

Piper Sandler updates rating for NeoGenomics ( $NEO ) to Overweight, target set at 12 → 11.

0 · Reply

rusty8350 Aug. 1 at 6:52 PM

$NEO Of course the rest of the market pumps and this one dumps and now vice versa 🤣

0 · Reply

ValueVester Aug. 1 at 6:25 PM

$NEO Pretty evident that the smart money is moving in at this level. They will be out at $10 for their double.

0 · Reply

brijith86 Aug. 1 at 1:15 PM

$NEO lets close it today at 4.40 or 4.50

0 · Reply

DriveForShow Jul. 31 at 9:23 PM

$NEO Brutal!!! Regressed back to 2015 numbers.

0 · Reply

getem2011 Jul. 31 at 7:40 PM

$NEO the downfall needs to be studied. It’s sad to see a company that does a lot of good in the world be so mismanaged.

0 · Reply

Kat_Harington Jul. 31 at 7:21 PM

$NEO so when’s the delistment scheduled

0 · Reply

AnyMonkey Jul. 31 at 6:42 PM

$NEO opened position under $5 today

2 · Reply

brijith86 Jul. 31 at 2:25 PM

$NEO they added 30 million share for nearly 150 million dollars

0 · Reply

Thestocktraderhubzee Jul. 31 at 10:17 AM

WATCHLIST JUL 31 2025 $UPS PeriShip Global Enters 3-Year UPS Partnership To Enhance Time-Sensitive And Perishable Shipment Logistics $QRVO Loop Capital Maintains Hold on Qorvo, Raises Price Target to $90 $TMDX TransMedics Group shares are trading higher after the company reported better-than-expected Q2 EPS results and raised its FY25 sales guidance above estimates. $NEO Morgan Stanley Maintains Equal-Weight on NeoGenomics, Lowers Price Target to $8 $ERIC Ericsson Strengthens Strategic Collaboration With SoftBank To Support 5G Standalone Rollout, Operational Efficiency, And Digital Leadership

0 · Reply

NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy

Jul 29, 2025, 4:54 PM EDT - 5 days ago

NeoGenomics, Inc. (NEO) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 7:05 AM EDT - 6 days ago

NeoGenomics Reports Second Quarter 2025 Results

Jul 1, 2025, 7:05 AM EDT - 4 weeks ago

NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025

Jun 30, 2025, 7:05 AM EDT - 5 weeks ago

NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care

Jun 24, 2025, 7:05 AM EDT - 5 weeks ago

NeoGenomics Appoints Dr. Marjorie Green to Board of Directors

May 28, 2025, 7:10 AM EDT - 2 months ago

NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025

May 22, 2025, 7:10 AM EDT - 2 months ago

NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer

May 20, 2025, 7:05 AM EDT - 2 months ago

NeoGenomics to Participate in Upcoming June Investor Conferences

May 1, 2025, 7:05 AM EDT - 3 months ago

NeoGenomics Pays Off 1.25% Convertible Senior Notes

Apr 30, 2025, 9:00 AM EDT - 3 months ago

NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade)

Apr 29, 2025, 12:18 PM EDT - 3 months ago

NeoGenomics, Inc (NEO) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 8:00 AM EDT - 3 months ago

NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

Apr 29, 2025, 7:30 AM EDT - 3 months ago

NeoGenomics Reports First Quarter 2025 Results

Apr 22, 2025, 7:05 AM EDT - 3 months ago

NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting

Apr 8, 2025, 7:05 AM EDT - 4 months ago

NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025

Apr 7, 2025, 7:05 AM EDT - 4 months ago

NeoGenomics Completes Acquisition of Pathline

Apr 1, 2025, 7:05 AM EDT - 4 months ago

Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

Mar 10, 2025, 7:00 AM EDT - 5 months ago

NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline

Feb 28, 2025, 3:39 AM EST - 5 months ago

NeoGenomics: Decent Fundamentals, But Still Overvalued

Feb 24, 2025, 7:05 AM EST - 5 months ago

NeoGenomics to Participate in Upcoming Investor Conferences

Feb 18, 2025, 12:22 PM EST - 5 months ago

NeoGenomics, Inc (NEO) Q4 2024 Earnings Call Transcript

Feb 18, 2025, 7:05 AM EST - 5 months ago

NeoGenomics Reports Fourth Quarter and Full Year 2024 Results

Jan 29, 2025, 8:05 AM EST - 6 months ago

NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025

Jan 15, 2025, 7:05 AM EST - 7 months ago

NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan

Jan 10, 2025, 7:05 AM EST - 7 months ago

NeoGenomics Announces Chief Executive Officer Succession

Jan 6, 2025, 7:55 AM EST - 7 months ago

NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 8:05 AM EST - 8 months ago

NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma

Dec 9, 2024, 8:10 AM EST - 8 months ago

NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting

Dec 5, 2024, 7:00 AM EST - 8 months ago

ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research

Nov 19, 2024, 8:15 AM EST - 9 months ago

NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment

Nov 14, 2024, 8:10 AM EST - 9 months ago

Felicia Williams Joins NeoGenomics Board of Directors

Nov 8, 2024, 7:00 AM EST - 9 months ago

NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 5, 2024, 1:27 PM EST - 9 months ago

NeoGenomics, Inc. (NEO) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 7:00 AM EST - 9 months ago

NeoGenomics Reports Third Quarter 2024 Results

Oct 22, 2024, 8:10 AM EDT - 10 months ago

NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test

Oct 15, 2024, 7:30 AM EDT - 10 months ago

NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024

Oct 8, 2024, 8:10 AM EDT - 10 months ago

NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia

Oct 2, 2024, 12:10 PM EDT - 10 months ago

NeoGenomics Inc (NEO) Shares Up 3.95% on Oct 2

Sep 23, 2024, 6:47 PM EDT - 11 months ago

NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation

Sep 11, 2024, 8:05 AM EDT - 11 months ago

NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment

Aug 29, 2024, 8:05 AM EDT - 1 year ago

NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Jul 29, 2024, 8:14 PM EDT - 1 year ago

NeoGenomics, Inc. (NEO) Q2 2024 Earnings Call Transcript

Jul 29, 2024, 4:05 PM EDT - 1 year ago

NeoGenomics Reports Second Quarter 2024 Results

Jul 9, 2024, 7:00 AM EDT - 1 year ago

NeoGenomics to Report Second Quarter 2024 Financial Results on July 29, 2024

Jun 13, 2024, 8:00 AM EDT - 1 year ago

Fort Myers' Mayor to Proclaim June as NeoGenomics' Commitment to Cancer Month

Jun 10, 2024, 1:00 AM EDT - 1 year ago

Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing

FLGT

JarvisFlow Aug. 4 at 3:59 PM

Piper Sandler updates rating for NeoGenomics ( $NEO ) to Overweight, target set at 12 → 11.

0 · Reply

rusty8350 Aug. 1 at 6:52 PM

$NEO Of course the rest of the market pumps and this one dumps and now vice versa 🤣

0 · Reply

ValueVester Aug. 1 at 6:25 PM

$NEO Pretty evident that the smart money is moving in at this level. They will be out at $10 for their double.

0 · Reply

brijith86 Aug. 1 at 1:15 PM

$NEO lets close it today at 4.40 or 4.50

0 · Reply

DriveForShow Jul. 31 at 9:23 PM

$NEO Brutal!!! Regressed back to 2015 numbers.

0 · Reply

getem2011 Jul. 31 at 7:40 PM

$NEO the downfall needs to be studied. It’s sad to see a company that does a lot of good in the world be so mismanaged.

0 · Reply

Kat_Harington Jul. 31 at 7:21 PM

$NEO so when’s the delistment scheduled

0 · Reply

AnyMonkey Jul. 31 at 6:42 PM

$NEO opened position under $5 today

2 · Reply

brijith86 Jul. 31 at 2:25 PM

$NEO they added 30 million share for nearly 150 million dollars

0 · Reply

Thestocktraderhubzee Jul. 31 at 10:17 AM

0 · Reply

brijith86 Jul. 30 at 7:13 PM

$NEO dont listen to bulls this what the performance of this stock .

0 · Reply

brijith86 Jul. 30 at 7:10 PM

$NEO come on guys lets do it

0 · Reply

brijith86 Jul. 30 at 7:09 PM

$NEO rumors abt offering spreading

0 · Reply

brijith86 Jul. 30 at 6:30 PM

$NEO 1.7 million ready to pick up with low borrowing cost

0 · Reply

SQUEAKSBANDIT Jul. 30 at 3:09 PM

$NEO huge block over 1MM share buy just crossed inst or insider ?

0 · Reply

brijith86 Jul. 30 at 2:56 PM

$NEO they are burning 45 million each every quarter. There is a high a chance for offering soon be careful. My advice is to short it with 100% confidence.

1 · Reply

brijith86 Jul. 30 at 2:48 PM

$NEO can we close this pos at 4.80

0 · Reply

Thestocktraderhubzee Jul. 30 at 11:10 AM

$NEO NeoGenomics Launches PanTracer LBx Blood-Based Genomic Profiling Test

0 · Reply

JarvisFlow Jul. 30 at 10:30 AM

Needham updates rating for NeoGenomics ( $NEO ) to Buy, target set at 8.5 → 8.

0 · Reply

BioGem Jul. 30 at 8:58 AM

$NEO I am adding to my short here. As per my previous post, all still apply. -Although their cash is better than I expected, but their current liabilities have skyrocketed in Q2, which means they will post a heavy cash burn in Q3. -Basic shares continue a hefty dilution as well.

0 · Reply

msufans Jul. 30 at 1:26 AM

$NEO just bought hundreds of shares. LT here

0 · Reply

JarvisFlow Jul. 29 at 10:00 PM

William Blair has adjusted their stance on NeoGenomics ( $NEO ), setting the rating to Market Perform.

0 · Reply

Market Cap	666.56M
Revenue (ttm)	660.57M
Net Income (ttm)	-78.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-11.92%
Debt to Equity Ratio	0.23

Volume	4,529,100
Avg Vol	2,293,270
Day's Range	N/A - N/A
Shares Out	129.18M
Stochastic %K	23%
Beta	1.55
Analysts	Sell
Price Target	$11.10